Kaleido Biosciences, Inc.KLDOOTCMARKET
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank40
3Y CAGR-40.5%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-40.5%/yr
Annual compound
Percentile
P40
Within normal range
vs 3Y Ago
0.2x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2021 | 21.15% |
| 2020 | -12.87% |
| 2019 | 52.71% |
| 2018 | 100.37% |
| 2017 | 166.97% |
| 2016 | 0.00% |